Awards for Sir Demis Hassabis, John Jumper and Geoffrey Hinton recognise how AI is changing our world
It is too early to know whether the prompt response to the virus is enough to turn the tide
Also in this newsletter: How greener corporate car fleets could boost competitiveness and the climate goals
US biotech researches treatments to reduce muscle loss from blockbuster diet medicines
International collaboration plotted 149 metres of biological wiring in fruit fly
The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’
Artificial intelligence used to help researchers plan experiments and better predict outcomes
Drugmaker’s CEO sees chance to widen use of anti-obesity medications for ‘health maintenance’
Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
The next stage in the war on cancer may be enlisting patients’ own blood cells to fight the disease
The reduced effectiveness of antibiotics risks severe disruption to the global economy
The lessons learnt from drug-resistant tuberculosis offer a path to beating back the ‘silent pandemic’ of antimicrobial resistance
Emmanuel Hanon criticises former company’s drug after he raises $100mn for rival product
Gavi chief Sania Nishtar offers rich nations long-term payment options for life-saving jabs
Lack of appointments blamed for fall in take-up of key vaccinations
But the healthcare system in the US still struggles to provide adequate care for those with serious mental illness
Foundation says about 40mn children are at risk of stunted growth as climate change worsens food security
Results offer hope of progress in combating bladder tumours and some forms of breast cancer
High rates of vomiting among those who took strong doses in trials have unsettled investors
Company’s chief oncology officer says reforms risk discouraging treatments for paediatric and rare conditions
Rita Charon believes that letting patients tell their own stories is the best way to fix a broken system
Some opt for a data-led utilitarian approach; others say treat contributions like an investment portfolio
More aggressive actions and better co-ordinated responses needed to contain viruses, say public health experts
Flying blind is dangerous. Technology can build on the basics of local and national data collection
Issue hampers effort to exploit mRNA technology’s promise in tackling deadly viral outbreaks
